The phrase "a composite of death" is correct and usable in written English.
It can be used in contexts discussing themes of mortality, art, literature, or philosophical concepts related to death.
Example: "The artist's latest work is a composite of death, exploring the fragility of life through haunting imagery."
Alternatives: "a blend of death" or "a mixture of death".
The primary outcome measure was a composite of death or surgical aortic valve replacement (AVR).
The primary outcome is a composite of death (any cause), cardiac arrest, acute myocardial infarction, stroke, myocardial revascularization, amputation for peripheral arterial disease, or hospitalization for unstable angina.
At 30 days, all patients were free of the primary clinical outcomes defined as a composite of death, myocardial infarction, or repeat target vessel revascularization, and there were no major bleeding complications.
The primary outcome was a composite of death from any cause or hospitalization for worsening heart failure.
The 3-year incidence of death; cardiac rehospitalization; and a composite of death, myocardial infarction, stroke, cardiac rehospitalization, and revascularization were 13.0%, 43.5%, and 52.2%, respectively.
METHODS AND RESULTS: The primary end point was a composite of death, Q-wave myocardial infarction, and a large reversible thallium defect at 3 years.
The meta-analytic rate of 30-day freedom from a composite of death, target limb amputation, and reintervention was 99.9%9595% CI 100.0-90.0100.0-90.0%
The primary end point was a composite of death, myocardial infarction, hospitalization for congestive heart failure (without renal replacement therapy), and stroke.
At six months, the primary end point - a composite of death, reinfarction, disabling stroke, and ischemia-driven revascularization of the target vessel - had occurred in 20.0percentt of patients after PTCA, 16.5percentt after PTCA plus abciximab, 11.5 percent after stenting, and 10.2 percent after stenting plus abciximab (P<0.001).
Compared with placebo CABG patients, vorapaxar-treated patients had a 45% lower rate of the primary endpoint (i.e., a composite of death, myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization during index hospitalization) (HR: 0.55; 95% CI: 0.36 to 0.83; p = 0.005), with a significant interaction (p = 0.012).
Secondary end points included the number of patients discontinuing beta-blockade, median dose achieved, and a composite of death, rehospitalization, unscheduled visit for HF, or > or =50% increase in oral diuretic, new oral diuretic, or any intravenous therapy with diuretics, inotropes, or other vasoactive agents.
